Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Niemann-Pick Disease Type C Market Insight, Epidemiology and Market Forecast - 2032, Featuring Zevra Therapeutics, Azafaros, Cyclo Therapeutics and IntraBio [Yahoo! Finance]
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at Ascendiant Capital Markets. They set a "buy" rating and a $2.60 price target on the stock.
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]